Ryan Zurakowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8965019/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Naive infection predicts reservoir diversity and is a formidable hurdle to HIV eradication. JCI Insight, 2021, 6, .	2.3	15
2	Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. Cellular and Molecular Bioengineering, 2020, 13, 259-284.	1.0	5
3	An Integrated Spatial Dynamics—Pharmacokinetic Model Explaining Poor Penetration of Anti-retroviral Drugs in Lymph Nodes. Frontiers in Bioengineering and Biotechnology, 2020, 8, 667.	2.0	8
4	Next-Generation Sequencing in a Direct Model of HIV Infection Reveals Important Parallels to and Differences from In Vivo Reservoir Dynamics. Journal of Virology, 2020, 94, .	1.5	6
5	Persistence of an intact HIV reservoir in phenotypically naive T cells. JCI Insight, 2020, 5, .	2.3	33
6	Optimal control modulation of HIV reservoir formation rate by antigen infusion *. , 2019, 2019, 5662-5667.		0
7	Positive Feedback Through Inflammation Creates Bistable Behavior in HIV Tissue Sanctuaries. , 2019, 2019, 3456-3461.		2
8	HIV 2-LTR experiment design optimization. PLoS ONE, 2018, 13, e0206700.	1.1	2
9	Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. Retrovirology, 2018, 15, 15.	0.9	29
10	Synaptic transmission may provide an evolutionary benefit to HIV through modulation of latency. Journal of Theoretical Biology, 2018, 455, 261-268.	0.8	4
11	Experiment design for early molecular events in HIV infection. , 2017, 2017, 122-127.		0
12	The effect of multiplicity of infection on the temperateness of a bacteriophage: Implications for viral fitness. , 2017, , .		0
13	Implications of measurement assay type in design of HIV experiments. , 2017, 2017, 4106-4111.		0
14	Order preservation of expected information content using Unscented Transform approximation of multivariate prior distributions in HIV 2-LTR experiment design. , 2016, 2016, 5597-5602.		3
15	Prospective HIV clinical trial comparison by expected Kullback-Leibler Divergence. , 2016, 2016, 1295-1300.		7
16	Recursive estimation with quantized and censored measurements. , 2016, , .		3
17	Increased inflammation in sanctuary sites may explain viral blips in HIV infection. IET Systems Biology, 2016, 10, 153-166.	0.8	3
18	The Tobit Kalman Filter: An Estimator for Censored Measurements. IEEE Transactions on Control Systems Technology, 2016, 24, 365-371.	3.2	79

RYAN ZURAKOWSKI

#	Article	IF	CITATIONS
19	Using the Tools we Have: Low-efficacy Vaccines and HIV. EBioMedicine, 2015, 2, 1867-1868.	2.7	1
20	Nonlinear estimators for censored data: A comparison of the EKF, the UKF and the Tobit Kalman filter. , 2015, , .		31
21	Estimation of saturated data using the Tobit Kalman filter. , 2014, , .		23
22	Analysis of HIV-1 compartmental model parameters using Bayesian MCMC estimation. , 2014, , .		1
23	Evaluation of HIV 2-LTR formation models using monotone system theory. , 2014, , .		2
24	Estimation of mobile vehicle range & position using the tobit Kalman filter. , 2014, , .		9
25	Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification. Journal of Theoretical Biology, 2014, 345, 61-69.	0.8	20
26	HIV-1 persistence in CD4+ T cells with stem cell–like properties. Nature Medicine, 2014, 20, 139-142.	15.2	379
27	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065.	1.5	242
28	Optimal multi-drug approaches for reduction of the latent pool in HIV. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2014, 47, 784-789.	0.4	0
29	Ballistic Roll Estimation using EKF Frequency Tracking and Adaptive Noise Cancellation. IEEE Transactions on Aerospace and Electronic Systems, 2013, 49, 2546-2553.	2.6	22
30	Modelling HIV-1 2-LTR dynamics following raltegravir intensification. Journal of the Royal Society Interface, 2013, 10, 20130186.	1.5	39
31	Conditions for invasion of synapse-forming HIV variants. , 2013, , .		4
32	Modeling Uncertainty in Single-Copy Assays for HIV. Journal of Clinical Microbiology, 2012, 50, 3381-3382.	1.8	15
33	Kalman filter-based tracking of multiple similar objects from a moving camera platform. , 2012, , .		4
34	Resistance evolution in HIV — Modeling when to intervene. , 2012, 2012, 4053-4058.		1
35	A compartment based model for the formation of 2-LTR circles after raltegravir intensification. , 2012, , .		6
36	Robust Closed-Loop Minimal Sampling Method for HIV Therapy Switching Strategies. IEEE Transactions on Biomedical Engineering, 2012, 59, 2227-2234.	2.5	7

RYAN ZURAKOWSKI

#	Article	IF	CITATIONS
37	HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. PLoS ONE, 2012, 7, e40198.	1.1	71
38	Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching. , 2011, 2011, 116-9.		3
39	Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy. PLoS ONE, 2011, 6, e27047.	1.1	22
40	Modeling and analysis of gene-therapeutic combination chemotherapy for pancreatic cancer. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2011, 44, 14217-14222.	0.4	1
41	Nonlinear observer output-feedback MPC treatment scheduling for HIV. BioMedical Engineering OnLine, 2011, 10, 40.	1.3	21
42	Controlling the evolution of resistance. Journal of Process Control, 2011, 21, 367-378.	1.7	16
43	Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data. , 2011, 2011, 3585-8.		Ο
44	Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection. , 2011, , 5418-5419.		3
45	Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching. , 2010, 2010, 5155-5160.		6
46	Closed-loop minimal sampling method for determining viral-load minima during switching. , 2010, 2010, 460-461.		6
47	A generalized multi-strain model of HIV evolution with implications for drug-resistance management. , 2009, , .		10
48	A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment. , 2008, , .		10
49	Resistance Risk Management in HIV Therapy Switching with Explicit Quiescent T-Cell Modeling. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2008, 41, 10325-10330.	0.4	3
50	Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment. , 2007, , .		9
51	Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. Journal of Theoretical Biology, 2007, 245, 1-8.	0.8	24
52	A model predictive control based scheduling method for HIV therapy. Journal of Theoretical Biology, 2006, 238, 368-382.	0.8	150
53	Treatment scheduling for HIV using robust nonlinear model predictive control. Australian Journal of Electrical and Electronics Engineering, 2005, 2, 49-58.	0.7	2